Doctor Leads Push for Better Cancer Trial Representation

When breast cancer researcher Dr. Yehoda Martei saw the final slides of a major clinical trial presentation, the numbers stopped her cold. A breakthrough drug trial for breast cancer had enrolled more men than Black women, despite Black women facing 40% higher death rates from the disease than white women.

The inavolisib trial included just 0.6% Black patients. The drug still received FDA approval and became standard treatment, but Martei knew something had to change.

This isn't just one study's problem. Over the past five years, major cancer trials have consistently underrepresented the very populations hit hardest by the disease. The KEYNOTE-522 trial enrolled 4.8% Black patients, while NATALEE enrolled just 1.6%.

Martei, a medical oncologist at the University of Pennsylvania, explains why this matters beyond fairness. When trial participants don't reflect real-world populations, the science itself becomes flawed. Doctors prescribe treatments based on incomplete evidence, potentially missing how drugs work differently across diverse groups.

The issue affects more than just Black women. Rural populations, older adults, Hispanic women, and people from lower-income countries are all systematically left out of the research that shapes their treatment options.

The Ripple Effect

The medical community is finally taking action. Programs like the Robert A. Winn Excellence in Clinical Trials Award are training investigators who understand how to reach underrepresented communities and build the trust necessary for participation.

Federal agencies and medical societies are working on new guidelines to open eligibility requirements and bring trials to under-resourced areas. These changes recognize that decades of exclusion require long-term commitment and genuine community partnerships.

As precision medicine promises treatments tailored to individual patients, Martei asks the critical question: How precise can medicine be when the data excludes entire populations? The answer is driving real reform.

Medical researchers are expanding their networks, building relationships with community leaders, and redesigning trial access. These efforts create a foundation for research that actually serves everyone diagnosed with cancer, not just a narrow slice of patients.

The changes won't happen overnight, but the momentum is building toward clinical trials that look like the world they're meant to heal.